Owkin Receives European Medicines Agency Letter of Support for Innovative AI-Driven Approach to Oncology Trial Analysis
Two Owkin AI models significantly improve the discrimination accuracy for overall survival in hepatocellular carcinoma and mesothelioma.
- Two Owkin AI models significantly improve the discrimination accuracy for overall survival in hepatocellular carcinoma and mesothelioma.
- Therefore, Owkin is encouraged to use their approach in future trials and do additional prospective validation.
- Felix Balazard, Director of Optimized Development at Owkin said: "This EMA letter of support offers a clear regulatory path for integrating AI models based on histopathology into the analysis of randomized clinical trials.
- With Owkin's Federated Research Network, it can develop on-demand prognostic scores for other indications, which can further reduce clinical trial failure rates.